| Pfizer Pushes New Biotech Drugs Pfizer is developing improved versions of top-selling biotechnology drugs, becoming the latest big pharmaceutical maker to take aim at the biotech industry. online.wsj.com |
Drug-Benefits Fights Loom Navistar's plan to drop some retirees' prescription benefits is turning into a skirmish that is likely to be replayed at other U.S. companies. online.wsj.com |
Genentech's New Option for Breast Cancer Patients The Burrill Report submits: By Michael FitzhughGenentech (DNA), a subsidiary of Roche, has submitted its new breast cancer drug to the FDA for approval, the company says, bringing closer to the market a new option for women for whom other breast cancer drugs have proven ineffective.Complete Story » seekingalpha.com |
Court Backs Injunction Blocking Generic Versions of Lilly's Evista A federal appeals court affirmed a lower-court ruling that will block generic versions of Lilly's osteoporosis drug Evista from becoming available in the U.S. until 2014. online.wsj.com |
Proposed Rules Rankle Health Insurers Regulators issued draft rules on how the companies must account for how much they spend directly on patients' medical care. online.wsj.com |